Cost-effectiveness of alternative minimum recall intervals between whole blood donations.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
09
2020
accepted:
25
07
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
20
8
2022
Statut:
epublish
Résumé
The INTERVAL trial showed shorter inter-donation intervals could safely increase the frequency of whole-blood donation. We extended the INTERVAL trial to consider the relative cost-effectiveness of reduced inter-donation intervals. Our within-trial cost-effectiveness analysis (CEA) used data from 44,863 whole-blood donors randomly assigned to 12, 10 or 8 week (males), and 16, 14 or 12 week inter-donation intervals (females). The CEA analysed the number of whole-blood donations, deferrals including low- haemoglobin deferrals, and donors' health-related quality of life (QoL) to report costs and cost-effectiveness over two years. The mean number of blood donation visits over two years was higher for the reduced interval strategies, for males (7.76, 6.60 and 5.68 average donations in the 8-, 10- and 12- week arms) and for females (5.10, 4.60 and 4.01 donations in the 12-, 14- and 16- week arms). For males, the average rate of deferral for low haemoglobin per session attended, was 5.71% (8- week arm), 3.73% (10- week), and 2.55% (12- week), and for females the rates were: 7.92% (12-week), 6.63% (14- week), and 5.05% (16- week). Donors' QoL was similar across strategies, although self-reported symptoms were increased with shorter donation intervals. The shorter interval strategies increased average cost, with incremental cost-effectiveness ratios of £9.51 (95% CI 9.33 to 9.69) per additional whole-blood donation for the 8- versus 12- week interval for males, and £10.17 (95% CI 9.80 to 10.54) for the 12- versus 16- week interval arm for females. Over two years, reducing the minimum donation interval could provide additional units of whole-blood at a small additional cost, including for those donor subgroups whose blood type is in relatively high demand. However, the significance of self-reported symptoms needs to be investigated further before these policies are expanded.
Sections du résumé
BACKGROUND
The INTERVAL trial showed shorter inter-donation intervals could safely increase the frequency of whole-blood donation. We extended the INTERVAL trial to consider the relative cost-effectiveness of reduced inter-donation intervals.
METHODS
Our within-trial cost-effectiveness analysis (CEA) used data from 44,863 whole-blood donors randomly assigned to 12, 10 or 8 week (males), and 16, 14 or 12 week inter-donation intervals (females). The CEA analysed the number of whole-blood donations, deferrals including low- haemoglobin deferrals, and donors' health-related quality of life (QoL) to report costs and cost-effectiveness over two years.
FINDINGS
The mean number of blood donation visits over two years was higher for the reduced interval strategies, for males (7.76, 6.60 and 5.68 average donations in the 8-, 10- and 12- week arms) and for females (5.10, 4.60 and 4.01 donations in the 12-, 14- and 16- week arms). For males, the average rate of deferral for low haemoglobin per session attended, was 5.71% (8- week arm), 3.73% (10- week), and 2.55% (12- week), and for females the rates were: 7.92% (12-week), 6.63% (14- week), and 5.05% (16- week). Donors' QoL was similar across strategies, although self-reported symptoms were increased with shorter donation intervals. The shorter interval strategies increased average cost, with incremental cost-effectiveness ratios of £9.51 (95% CI 9.33 to 9.69) per additional whole-blood donation for the 8- versus 12- week interval for males, and £10.17 (95% CI 9.80 to 10.54) for the 12- versus 16- week interval arm for females.
CONCLUSIONS
Over two years, reducing the minimum donation interval could provide additional units of whole-blood at a small additional cost, including for those donor subgroups whose blood type is in relatively high demand. However, the significance of self-reported symptoms needs to be investigated further before these policies are expanded.
Identifiants
pubmed: 35976959
doi: 10.1371/journal.pone.0272854
pii: PONE-D-20-28101
pmc: PMC9384981
doi:
Substances chimiques
Hemoglobins
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0272854Subventions
Organisme : British Heart Foundation
ID : CH/12/2/29428
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/13/13/30194
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/18/13/33946
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Blood Transfus. 2016;2016:8624230
pubmed: 27293985
Lancet Haematol. 2019 Oct;6(10):e510-e520
pubmed: 31383583
Transfusion. 2015 Nov;55(11):2641-4
pubmed: 26075584
Transfus Med. 2000 Mar;10(1):5-11
pubmed: 10760198
Transfusion. 2010 Dec;50(12 Pt 2):2778-84
pubmed: 21128949
Transfusion. 2012 Sep;52(9):1983-8
pubmed: 22313531
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Transfus Med. 2019 Apr;29 Suppl 1:42-51
pubmed: 29767450
Vox Sang. 2006 May;90(4):308-15
pubmed: 16635074
Med Care. 2004 Sep;42(9):851-9
pubmed: 15319610
Int J Technol Assess Health Care. 2005 Spring;21(2):234-9
pubmed: 15921064
Transfusion. 2018 Dec;58(12):2861-2867
pubmed: 30265754
Lancet. 2013 May 25;381(9880):1866-75
pubmed: 23706803
Trials. 2016 Sep 20;17(1):458
pubmed: 27645285
Transfusion. 2007 Aug;47(8):1514-23
pubmed: 17655597
Transfusion. 2016 Aug;56(8):1994-2004
pubmed: 27237451
Lancet. 2017 Nov 25;390(10110):2360-2371
pubmed: 28941948
Transfusion. 2011 Mar;51(3):539-47
pubmed: 20849410
Transfusion. 2007 Aug;47(2 Suppl):197S-200S; discussion 201S
pubmed: 17651350
Transfus Med Rev. 2014 Jan;28(1):18-22
pubmed: 24332843
Health Policy. 2008 May;86(2-3):276-87
pubmed: 18160122
Transfusion. 2012 Sep;52(9):1880-8
pubmed: 22313024
Transfusion. 2017 Mar;57(3):564-570
pubmed: 27943371
Health Econ. 1998 Aug;7(5):455-63
pubmed: 9753379
Transfus Med. 2003 Aug;13(4):205-18
pubmed: 12880391
Trials. 2014 Sep 17;15:363
pubmed: 25230735